License Agreement (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
License Agreement (Details Narrative) - USD ($)	Aug. 23, 2020	Feb. 28, 2022	Dec. 31, 2021	Jun. 30, 2023	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Convertible shares		6,000,000		7,261,087
Description of milestone	Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company issued 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021.
Description of milestone one	29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021.
Description of milestone two	29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and
Description of milestone three	Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met.
Description of milestone four	$40,000 of royalties to be paid to 7 to Stand annually, on a quarterly basis. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval.
Paid for royalties				$ 23,852
Common stock issued for stock payable		$ 25,000		50,102
Gain recognized				10,166
Royalties and late fess				$ 10,000	$ 26,250
License Agreement [Member] \| Patents [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty of net sales	7.10%
License Agreement [Member] \| Patents [Member] \| Fabrizio De Silvestri [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Convertible shares	10,610,592

GlobeStar Therapeutics Corp 10-Q